Erlotinib

BindingDB Entry 50022536: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.

PubMed · 2025 · 844 citations · Full text

Medicine, Oncology, Pharmacology +17

Approval Summary for Erlotinib for Treatment of Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer after Failure of at Least One Prior Chemotherapy Regimen

John R. Johnson, Martin H. Cohen, Rajeshwari Sridhara et al. · Clinical Cancer Research · 2005 · 215 citations · Full text

Medicine, Oncology, Pharmacology +13

The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP™) predicts in vivo metabolic inhibition

Ashok Rakhit, Michael Pantze, Scott Fettner et al. · European Journal of Clinical Pharmacology · 2007 · 122 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS

Irina Andriamanana, Inès Gana, Bénédicte Duretz et al. · Journal of Chromatography B · 2013 · 117 citations

Medicine, Oncology, Pharmacology +10

High throughput routine determination of 17 tyrosine kinase inhibitors by LC–MS/MS

C Merienne, Marine Rousset, Dominique Ducint et al. · Journal of Pharmaceutical and Biomedical Analysis · 2017 · 117 citations

Pharmacy, Medicinal Chemistry, Pharmacology +10